27 Recruiting Studies Using Polatuzumab Vedotin
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Polatuzumab Vedotin
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
📍 The University of Arizona Cancer Center - North Campus /ID# 242219 — Tucson, Arizona
Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 City of Hope Cancer Center — Duarte, California
Non-Hodgkin Lymphoma
View Study & Checklist ➔Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
📍 University of Alabama at Birmingham School of Medicine — Birmingham, Alabama
B-cell Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
📍 University of Rochester — Rochester, New York
DLBCL
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
📍 Washington University School of Medicine — St Louis, Missouri
Lymphoma, Follicular
View Study & Checklist ➔An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Large B-Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
📍 University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Aggressive Non-Hodgkin Lymphoma
View Study & Checklist ➔Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Diffuse Large B-Cell Lymphoma Unclassifiable
View Study & Checklist ➔Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
📍 Karmanos Cancer Institute — Detroit, Michigan
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
📍 Local Institution - 162 — Birmingham, Alabama
Lymphoma, B-Cell
View Study & Checklist ➔Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
📍 Washington University School of Medicine — St Louis, Missouri
Post-transplant Lymphoproliferative Disorder
View Study & Checklist ➔Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
📍 Rhode Island Hospital — Providence, Rhode Island
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
📍 Banner University Medical Center - Tucson — Tucson, Arizona
Diffuse Large B-Cell Lymphoma
View Study & Checklist ➔Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
📍 Mount Sinai- Icahn School of Medicine — New York, New York
Richter Syndrome
View Study & Checklist ➔The CARDIOPROTECT Trial
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Diffuse Large B-cell Lymphoma (DLBCL)
View Study & Checklist ➔Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
View Study & Checklist ➔A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
📍 Infirmary Cancer Care ( Site 0157) — Mobile, Alabama
Lymphoma, Large B-Cell, Diffuse
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
📍 Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
View Study & Checklist ➔A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
📍 M D Anderson Cancer Center — Houston, Texas
Hodgkin Lymphoma
View Study & Checklist ➔Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
📍 New York Medical Center — Valhalla, New York
B-cell Lymphoma
View Study & Checklist ➔Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
📍 Winship Cancer Institute at Emory University — Atlanta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
📍 City of Hope Medical Center — Duarte, California
Recurrent Grade 1 Follicular Lymphoma
View Study & Checklist ➔Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
📍 University of Miami — Miami, Florida
CNS Lymphoma
View Study & Checklist ➔